Monitor upcoming clinical data readouts in Q2 and Q4 2026 as key value drivers, while watching for any updates on the RGX-121 regulatory pathway. The improved cash runway reduces near-term dilution risk.
Price Chart
Executive Summary
REGENXBIO reported financial results for Q4 and full year 2025, showing increased revenue driven by collaboration income and royalty growth, while net loss narrowed year-over-year. The company highlighted clinical progress in its gene therapy pipeline, including upcoming data readouts for RGX-202 in Duchenne muscular dystrophy and sura-vec in wet AMD, but also disclosed ongoing regulatory challenges with RGX-121 following a clinical hold and CRL from the FDA.
Key Financial Metrics
Key Facts
- Revenue increased to $170.4M for FY2025 (from $83.3M in FY2024), driven by $72.9M in upfront license revenue from Nippon Shinyaku partnership and higher Zolgensma/Itvisma royalties
- Net loss narrowed to $193.9M for FY2025 (from $227.1M in FY2024) despite higher R&D and G&A expenses
- Cash position was $240.9M as of December 31, 2025, expected to fund operations into early 2027
- RGX-121 received a Complete Response Letter from FDA and remains on clinical hold, creating regulatory uncertainty
- Multiple near-term catalysts expected in 2026 including topline data for RGX-202 (early Q2) and sura-vec (Q4)
Financial Impact
Revenue nearly doubled year-over-year to $170.4M, while net loss decreased by $33.2M. Cash runway extends into early 2027.
Risk Factors
- Regulatory uncertainty surrounding RGX-121 approval pathway after CRL and clinical hold
- Increasing R&D expenses ($228.3M in 2025) could pressure cash runway if milestones are delayed
- Dependence on partnership revenues and royalty payments creates revenue volatility
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 3 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 8-K Filing (Primary) | 0001193125-26-092566 |
| Document: 0001193125-26-092566-index.html | 0001193125-26-092566 |
| Document: 0001193125-26-092566.txt | 0001193125-26-092566 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Aug 27, 2026 5w ago | Insider Buy | $9.66 $7.47 | ▼ −22.67% | ▼ −22.93% | $7.43 (−23.08%) |
Aug 25, 2026 5w ago | 8-K | $9.38 $7.24 | ▼ −22.81% | ▼ −23.04% | $7.43 (−20.79%) |
Aug 6, 2026 8w ago | 8-K | $11.28 $9.20 | ▼ −18.44% | ▼ −19.04% | $7.43 (−34.13%) |
Aug 3, 2026 8w ago | Press Release | $9.96 $9.50 | ▼ −4.62% | ▼ −5.86% | $7.43 (−25.40%) |
Jul 20, 2026 10w ago | 8-K | $10.32 $11.33 | ▼ −9.79% | ▼ −5.67% | $7.43 (+28.00%) |
Jul 17, 2026 11w ago | Press Release | $9.89 $10.77 | ▼ −8.85% | ▼ −4.40% | $7.43 (+24.87%) |
Jun 29, 2026 13w ago | 8-K | $11.83 $9.73 | ▼ −17.75% | ▼ −17.47% | $7.43 (−37.19%) |
Jun 3, 2026 17w ago | 8-K | $6.69 $13.28 | ▲ +98.51% | ▲ +99.51% | $7.43 (+11.06%) |
May 14, 2026 20w ago | 8-K | $6.25 $6.66 | ▲ +6.65% | ▲ +7.50% | $7.43 (+18.98%) |
Mar 5, 2026 30w ago | 8-K | $8.72 $8.53 | ▼ −2.18% | ▲ +1.61% | $7.43 (−14.79%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Try SecBot Free Coming soon: SecBot Pro with alerts, watchlists, and API access